Oxford Asset Management’s AstraZeneca AZN Stock Holding History

Oxford Asset Management’s Portfolio AZN Stock Details AZN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q1	–	Sell	-3,363	Closed	-$232K	–	797
2015 Q4	$232K	Buy	+3,363	New	+$220K	0.01%	782
2014 Q4	–	Sell	-9,920	Closed	-$710K	–	712
2014 Q3	$710K	Buy	+9,920	New	+$726K	0.02%	510
2013 Q3	–	Sell	-150,300	Closed	-$7.11M	–	794
2013 Q2	$7.11M	Buy	+150,300	New	+$7.65M	0.19%	154

Other funds holding AZN

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

EIP

Epoch Investment Partners New York $17.6B AUM 34.17% 1-Year Est. Return

Cambiar Investors Denver, Colorado $2.3B AUM 24.77% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

SCCM

Schafer Cullen Capital Management New York $491M AUM 41.48% 1-Year Est. Return

Putnam Investments Boston, Massachusetts $75.7B AUM 34.45% 1-Year Est. Return

Oxford Asset Management's AZN Position: Q1 2016 in Review

Oxford Asset Management sold out of AstraZeneca (AZN) in Q1 2016, closing a stake of 3,363 shares — an estimated $232K sold.

Oxford Asset Management first reported a position in AZN in Q2 2013 and held it in 3 quarters. The position peaked at $7.11M in Q2 2013. 390 funds tracked by Wall St. Rank hold AZN as of Q1 2016.

Oxford Asset Management reported no remaining AstraZeneca position as of Q1 2016 after selling out during the quarter.
Oxford Asset Management sold 3,363 AstraZeneca shares in Q1 2016, an estimated $232K.
Oxford Asset Management first reported a position in AstraZeneca in Q2 2013 and held it in 3 quarters.
Oxford Asset Management's AstraZeneca position peaked at $7.11M in Q2 2013.
390 funds tracked by Wall St. Rank held AstraZeneca as of Q1 2016.

Based on Oxford Asset Management's 13F filing for Q1 2016, filed 9 May 2016.